Yantai Dongcheng Pharmaceutical Group Co.,Ltd., together with its subsidiaries, engages in the manufacture and sale of biochemical API products in China. More Details
Solid track record with excellent balance sheet.
Share Price & News
How has Yantai Dongcheng Pharmaceutical GroupLtd's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 002675 is not significantly more volatile than the rest of CN stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: 002675's weekly volatility (6%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: 002675 underperformed the CN Biotechs industry which returned 47.9% over the past year.
Return vs Market: 002675 underperformed the CN Market which returned 22.3% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Yantai Dongcheng Pharmaceutical GroupLtd's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Yantai Dongcheng Pharmaceutical GroupLtd undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 002675 (CN¥19.07) is trading above our estimate of fair value (CN¥4.47)
Significantly Below Fair Value: 002675 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 002675 is good value based on its PE Ratio (37.2x) compared to the CN Biotechs industry average (51.9x).
PE vs Market: 002675 is poor value based on its PE Ratio (37.2x) compared to the CN market (30.2x).
Price to Earnings Growth Ratio
PEG Ratio: 002675 is poor value based on its PEG Ratio (1.5x)
Price to Book Ratio
PB vs Industry: 002675 is good value based on its PB Ratio (3.4x) compared to the CN Biotechs industry average (5.1x).
How is Yantai Dongcheng Pharmaceutical GroupLtd forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 002675's forecast earnings growth (24.6% per year) is above the savings rate (3.3%).
Earnings vs Market: 002675's earnings (24.6% per year) are forecast to grow faster than the CN market (21.2% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 002675's revenue (14% per year) is forecast to grow slower than the CN market (16.9% per year).
High Growth Revenue: 002675's revenue (14% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 002675's Return on Equity is forecast to be low in 3 years time (14%).
How has Yantai Dongcheng Pharmaceutical GroupLtd performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 002675 has high quality earnings.
Growing Profit Margin: 002675's current net profit margins (11.4%) are higher than last year (5.2%).
Past Earnings Growth Analysis
Earnings Trend: 002675's earnings have grown significantly by 22% per year over the past 5 years.
Accelerating Growth: 002675's earnings growth over the past year (150.4%) exceeds its 5-year average (22% per year).
Earnings vs Industry: 002675 earnings growth over the past year (150.4%) exceeded the Biotechs industry 34.9%.
Return on Equity
High ROE: 002675's Return on Equity (10.3%) is considered low.
How is Yantai Dongcheng Pharmaceutical GroupLtd's financial position?
Financial Position Analysis
Short Term Liabilities: 002675's short term assets (CN¥3.0B) exceed its short term liabilities (CN¥2.0B).
Long Term Liabilities: 002675's short term assets (CN¥3.0B) exceed its long term liabilities (CN¥536.9M).
Debt to Equity History and Analysis
Debt Level: 002675's debt to equity ratio (19.2%) is considered satisfactory.
Reducing Debt: 002675's debt to equity ratio has increased from 14% to 19.2% over the past 5 years.
Debt Coverage: 002675's debt is well covered by operating cash flow (63.7%).
Interest Coverage: 002675's interest payments on its debt are well covered by EBIT (15.6x coverage).
What is Yantai Dongcheng Pharmaceutical GroupLtd current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 002675's dividend (1.31%) is higher than the bottom 25% of dividend payers in the CN market (0.47%).
High Dividend: 002675's dividend (1.31%) is low compared to the top 25% of dividend payers in the CN market (1.87%).
Stability and Growth of Payments
Stable Dividend: 002675 has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: 002675's dividend payments have increased, but the company has only paid a dividend for 8 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (48.8%), 002675's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Yantai Dongcheng Pharmaceutical GroupLtd has no CEO, or we have no data on them.
Experienced Board: 002675's board of directors are not considered experienced ( 0.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Yantai Dongcheng Pharmaceutical Group Co.,Ltd.'s company bio, employee growth, exchange listings and data sources
- Name: Yantai Dongcheng Pharmaceutical Group Co.,Ltd.
- Ticker: 2675
- Exchange: SZSE
- Founded: 1998
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: CN¥15.298b
- Shares outstanding: 802.21m
- Website: https://www.dcb-group.com
Number of Employees
- Yantai Dongcheng Pharmaceutical Group Co.,Ltd.
- No.7 ChangBaiShan Road
- Yantai Development Zone
- Shandong Province
Yantai Dongcheng Pharmaceutical Group Co.,Ltd., together with its subsidiaries, engages in the manufacture and sale of biochemical API products in China. It offers heparin, chondroitin sulphate, and glucos...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/09 09:31|
|End of Day Share Price||2021/05/07 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.